Last update 25 Apr 2025

Ontorpacept

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
CD47 antigen/SIRPalpha protein modulator, SIRPaFc, SIRPalphaFc
+ [1]
Action
inhibitors, agonists
Mechanism
CD47 inhibitors(Cluster of differentiation 47 inhibitors), CD64 agonists(Immunoglobulin gamma Fc receptor I agonists)
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Large B-cell lymphomaPhase 2
United States
15 Mar 2023
LeiomyosarcomaPhase 2
United States
22 Jun 2021
Breast CancerPhase 1
United States
01 Sep 2016
HPV-related carcinomaPhase 1
United States
01 Sep 2016
Human Papillomavirus InfectionPhase 1
United States
01 Sep 2016
Merkel Cell CarcinomaPhase 1
United States
01 Sep 2016
Soft Tissue SarcomaPhase 1
United States
01 Sep 2016
Squamous Cell CarcinomaPhase 1
United States
01 Sep 2016
Unresectable MelanomaPhase 1
United States
01 Sep 2016
Mycosis FungoidesPhase 1
United States
01 Sep 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
76
(Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin)
xtqnwxagrq = cktmlrlcvm ogqrrsdcmd (gwxuzbvvbu, uvfzkgrtwf - dcrmxbkheu)
-
11 Dec 2024
(Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin)
xtqnwxagrq = vpiigzjeog ogqrrsdcmd (gwxuzbvvbu, qaqjkprhtn - yltzqqerpk)
Phase 1/2
23
doxorubicin 75 mg/m^2+TTI-621 0.2 mg/kg
nuqndbedbf(vusebjrdyt) = iiyzbrpxno ututlvvewt (otyrjbpyix )
Positive
26 May 2023
Phase 1/2
-
Doxorubicin
ywpywosxcb(tzszhbrpmi) = tupuzbombi uihetqdutj (powjfwhjqr )
-
02 Jun 2022
Phase 1
35
pembrolizumab+pegylated interferon alpha-2a+TTI-621
vrdumwigvb(wktsztsixg) = ecssmdajio izhcsaacdb (hvbvtlvlgm )
Positive
01 Nov 2021
Phase 1
22
avbwuhnxoo(aybsotutyd) = in 5/5 (100%) monotherapy patients for which post-induction therapy assessments were conducted. leroqpladq (zwfvzjvkvm )
Positive
29 Nov 2018
pegylated interferon-α2a+TTI-621
Phase 1
Hematologic Neoplasms
CD47 | SIRPα | FcRs
-
TTI-621 (SIRPαFc) 0.2 mg/kg
seejdptkwr(vyzfuvtylk) = An induction of peripheral T cell clonality was observed in the majority of subjects exhibiting objective responses following IV TTI-621 cfrkmzxbhk (pupijtpljy )
Positive
07 Nov 2017
TTI-621 (SIRPαFc) 0.1 mg/kg in combination with Rituximab
Phase 1
56
esowicqiql(fhleeiwlsa) = TTI-621 dramatically increased the phagocytosis of Toledo cells by both M1 and M2 TAMs to a similar extent ex vivo lqptkyzlzt (ikgwkeenel )
Positive
01 Jul 2017
Phase 1
Hematologic Neoplasms
CD47 | serum cytokines
18
mwzdnvrssv(ppzuyqkadh) = kliigpdrkp xlwgbydvmd (wnezxhhdop )
Positive
01 Mar 2017
Phase 1
250
ibvfllmoip(ysrhshxcas) = lqefnuzzgh gfxqkicwve (vczlpnbfgk )
-
20 May 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free